Ventyx Biosciences Inc

NASDAQ:VTYXUnited States

Ventyx Biosciences, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing a pipeline of small molecule product candidates to address a range of inflammatory diseases with unmet need. The Company’s pipeline includes VTX002 (S1P1R Modulator), VTX958 (TYK2 Inhibitor), and VTX2735 and VTX3232 (NLRP3 Inhibitor Portfolio). VTX002 is a sphingosine 1 phosphate receptor (S1P1R) modulator in Phase II development for patients with moderately to severely active ulcerative colitis (UC). VTX958 is an oral, selective clinical-stage inhibitor of tyrosine kinase type 2 (TYK2), an intracellular signaling kinase in the Janus kinase (JAK) family that regulates chronic inflammation in immune-mediated diseases. Its third product candidate, VTX2735, is a peripheral-targeted NOD-like receptor protein 3 (NLRP3) inflammasome inhibitor. In addition to VTX2735, it is also developing VTX3232, its lead CNS-penetrant NLRP3 inhibitor in Phase 1 development.

Contact Information

Headquarters

12790 El Camino Real, Suite 200SAN DIEGO, CA, United States 92130

Phone

858-945-2393

Fax

302-655-5049

Executives

Executive Chairperson of the Board

Sheila Gujrathi

President, Chief Executive Officer, Founder, Director

Raju Mohan

Chief Financial Officer

Martin Auster

Chief Operating Officer

Matthew Moore

Chief Scientific Officer

John Nuss